ecrin-mdr-crcClinical2009Malignant neoplasm of colon-C20 Malignant neoplasm of rectumAdvanced Solid TumorsMalignant neoplasm of colonMalignant neoplasm of rectumNeoplasmsMalignant Neoplasm Of RectumMalignant Neoplasm Of Colon-c20 Malignant Neoplasm Of RectumAdvanced Solid TumorsMalignant Neoplasm Of ColonNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2089537Taiwan11RDBiomarkerSorafenibPGPKMTDDLTS1ECRIN MDRCompletedfalseSorafenib Plus S-1 in Advanced Solid TumorsPrimary Objective: 1. To define the recommended dose for phase II study of S-1 combined with sorafenib 2. To evaluate the dose-limiting toxicities of the combination therapy Secondary Objectives: 1. To characterize the pharmacokinetics (PK) of sorafenib and S-1 in the combination therapy 2. To investigate the impact of genetic polymorphisms of metabolic genes on the PK of sorafenib and S-1, respectively, as well as on the toxicity profile of the combination. 3. To determine the changes of biomarkers between pre- and post-treatments.2009-11-152089537NCT01128998PER-015-10